Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

MIXED(18)
DRUG(4)
BIOLOGICAL(3)
recombinant interferon alfa
6 trials
phase_2
hoag-memorial-hospital-presbyterian
rituximab
4 trials
phase_2
hoag-memorial-hospital-presbyterian
aldesleukin
3 trials
phase_2
hoag-memorial-hospital-presbyterian
cyclophosphamide
2 trials
phase_2
hoag-memorial-hospital-presbyterian
therapeutic tumor infiltrating lymphocytes
1 trial
phase_2
hoag-memorial-hospital-presbyterian
filgrastim
1 trial
phase_2
hoag-memorial-hospital-presbyterian
doxorubicin hydrochloride
1 trial
phase_2
hoag-memorial-hospital-presbyterian
isotretinoin
1 trial
phase_2
hoag-memorial-hospital-presbyterian

+6 more interventions

14 unique interventions3 categories

Analytics

Trial Phases

Phase 29

Trial Status

Completed5
Other4

Role Distribution

Other Roles9

Activity Timeline

Clinical Trials (9)

NCT00002504Phase 2Completed
Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer
Chronic Myeloproliferative DisordersLeukemiaLymphoma+4 more
Studychair
NCT00002505Phase 2Completed
Tumor Cell Vaccine in Treating Patients With Advanced Cancer
Unspecified Adult Solid Tumor, Protocol Specific
Studychair
NCT00002506Phase 2Completed
Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer
Cervical CancerEsophageal CancerHead and Neck Cancer+3 more
Studychair
NCT00002733Phase 2Completed
Biological Therapy in Treating Patients With Metastatic Cancer
Kidney CancerMelanoma (Skin)Unspecified Adult Solid Tumor, Protocol Specific
Studychair
NCT00003091Phase 2Completed
High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma
Kidney CancerMelanoma (Skin)
Studychair
NCT00003605Phase 2Withdrawn
Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's Lymphoma
Lymphoma
Studychair
NCT00003663Phase 2Withdrawn
Rituximab and Dexamethasone in Treating Patients With Recurrent or Refractory Indolent Non-Hodgkin's Lymphoma
Lymphoma
Studychair
NCT00004039Phase 2Withdrawn
Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma
Lymphoma
Studychair
NCT00004040Phase 2Withdrawn
Monoclonal Antibody Therapy or Biological Therapy in Treating Patients With Chronic Lymphocytic Leukemia or Multiple Myeloma in Remission After Chemotherapy
LeukemiaMultiple Myeloma and Plasma Cell Neoplasm
Studychair

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Jorge Cortes, MD

M.D. Anderson Cancer Center

Related
24 trials

Shared therapeutic areas:

LeukemiaMyelodysplastic SyndromesChronic Myeloproliferative Disorders+3 more
Similarity Score12%

Steven A Rosenberg, M.D.

National Cancer Institute (NCI)

Related
32 trials

Shared therapeutic areas:

Cancer of the Uterine CervixLung CancerCancer of Kidney+1 more
Similarity Score8%

John D. Hainsworth, MD

SCRI Development Innovations, LLC

Related
26 trials

Shared therapeutic areas:

Lung CancerCancer of KidneyCancer of Esophagus+1 more
Similarity Score8%

Aminah Jatoi, MD

Mayo Clinic

Related
29 trials

Shared therapeutic areas:

Cancer of EsophagusLung CancerUnspecified Adult Solid Tumor, Protocol Specific+1 more
Similarity Score8%

Steven A. Rosenberg, MD, PhD

NCI - Surgery Branch

Related
29 trials

Shared therapeutic areas:

Melanoma (Skin)Cancer of KidneyUnspecified Adult Solid Tumor, Protocol Specific+1 more
Similarity Score8%

Zhenfeng Zhang, MD, PhD

Second Affiliated Hospital of Guangzhou Medical University

Related
21 trials

Shared therapeutic areas:

Lung CancerCancer of the Uterine CervixCancer of Esophagus+1 more
Similarity Score8%

Mary Horowitz, MD

Center for International Blood and Marrow Transplant Research

Related
24 trials

Shared therapeutic areas:

LeukemiaLymphomaMyelodysplastic Syndromes
Similarity Score6%

Mark Levine, MD

Ontario Clinical Oncology Group (OCOG)

Related
13 trials

Shared therapeutic areas:

Cancer of EsophagusCancer of Head and NeckLymphoma
Similarity Score6%

Areej El-Jawahri, MD

Massachusetts General Hospital

Related
21 trials

Shared therapeutic areas:

LymphomaMyelodysplastic Syndromes
Similarity Score4%

You Lu, MD

West China Hospital

Related
18 trials

Shared therapeutic areas:

Lung CancerCancer of the Uterine Cervix
Similarity Score4%

Publications (0)

No publications found for this investigator.

Clinical Trials (9)

Showing 9 of 9 trials

NCT00002504Phase 2StudyChair

Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer

Chronic Myeloproliferative DisordersLeukemiaLymphoma+4 more
Completed
NCT00002505Phase 2StudyChair

Tumor Cell Vaccine in Treating Patients With Advanced Cancer

Unspecified Adult Solid Tumor, Protocol Specific
Completed
NCT00002506Phase 2StudyChair

Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer

Cervical CancerEsophageal CancerHead and Neck Cancer+3 more
Completed
NCT00002733Phase 2StudyChair

Biological Therapy in Treating Patients With Metastatic Cancer

Kidney CancerMelanoma (Skin)Unspecified Adult Solid Tumor, Protocol Specific
Completed
NCT00003091Phase 2StudyChair

High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma

Kidney CancerMelanoma (Skin)
Completed
NCT00003605Phase 2StudyChair

Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's Lymphoma

Lymphoma
Withdrawn
NCT00003663Phase 2StudyChair

Rituximab and Dexamethasone in Treating Patients With Recurrent or Refractory Indolent Non-Hodgkin's Lymphoma

Lymphoma
Withdrawn
NCT00004039Phase 2StudyChair

Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma

Lymphoma
Withdrawn
NCT00004040Phase 2StudyChair

Monoclonal Antibody Therapy or Biological Therapy in Treating Patients With Chronic Lymphocytic Leukemia or Multiple Myeloma in Remission After Chemotherapy

LeukemiaMultiple Myeloma and Plasma Cell Neoplasm
Withdrawn

All 9 trials loaded